In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy

Session Poster session 2

Speaker Young Jun Park

Event : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Oral Anticoagulation
  • Session type : Poster Session

Authors : YJ Park (Seoul,KR), SS Lee (Seoul,KR), HB Gwag (Seoul,KR), KM Park (Seoul,KR), YK On (Seoul,KR), JS Kim (Seoul,KR), SJ Park (Seoul,KR)

YJ Park1 , SS Lee1 , HB Gwag1 , KM Park1 , YK On1 , JS Kim1 , SJ Park1 , 1Samsung Medical Center - Seoul - Korea Republic of ,


Chronic anticoagulation is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral anticoagulants (NOACs) are an alternative to VKAs but there are limited data to support their use in HCM. We sought to describe the pattern of use, thromboembolic events, bleeding in patients with HCM and AF treated with NOACs.

Data from patients treated with NOACs (n=158) and VKA (n=103)  were retrospectively collected. Annual rates of embolic events, serious bleeding and death were analysed and compared.

After median follow-up of 23.1 months , thromboembolic events (TIA/stroke and peripheral embolism) occurred in 6% of patients on oral anticoagulation. Major/clinically relevant bleeding occurred in 2.8% and the global mortality rate was 11.2%. Thromboembolic event rate was 0.89 per 100patient-years in the NOAC group vs. 1.24 in the VKA group [subhazard ratio (SHR) 0.52;95%CI:0.14-2.45; p=0.27]. Major/clinically relevant bleeding occurred in 0.52 per 100person-years in the NOAC group vs. 0.70 in the VKA group (SHR 1.28;95%CI 0.24-6.30; p=0.56). .

HCM patients with AF on NOACs showed similar embolic and bleeding rates to those on VKA.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are